Abstract
As first-generation antisense oligonucleotides, more than a dozen phosphorothioate oligodeoxynucleotides (PS ODNs) have been clinically developed, but only one has reached the market. To improve the drawbacks of PS ODNs, such as low affinity to target mRNA and non-specific binding to proteins, modified oligonucleotides with 2-modified sugars such as 2-O-(2-methoxy)ethyl and 2-F modification or with bridged sugars such as oxyalkylene linkages between 2-oxygen and 4-carbon, have been synthesized as 2-MOE, 2-F RNA, 2,4-BNA/LNA and ENA oligonucleotides. They have shown properties of higher affinity to complementary single-stranded RNA and DNA than those of PS ODNs due to their preorganized N-conformation. On the basis of the properties of these newly designed oligonucleotides, their in vitro and in vivo applications for gene silencing as true antisense oligonucleotides have been reported. In this review, antisense applications with these modified oligonucleotides are focused on.
Keywords: DNA oligonucleotides, bridged nucleosides, Gapmers, Duchenne muscular dystrophy, RNA polymerase II
Current Topics in Medicinal Chemistry
Title: True Antisense Oligonucleotides with Modified Nucleotides Restricted in the Nconformation
Volume: 7 Issue: 7
Author(s): Makoto Koizumi
Affiliation:
Keywords: DNA oligonucleotides, bridged nucleosides, Gapmers, Duchenne muscular dystrophy, RNA polymerase II
Abstract: As first-generation antisense oligonucleotides, more than a dozen phosphorothioate oligodeoxynucleotides (PS ODNs) have been clinically developed, but only one has reached the market. To improve the drawbacks of PS ODNs, such as low affinity to target mRNA and non-specific binding to proteins, modified oligonucleotides with 2-modified sugars such as 2-O-(2-methoxy)ethyl and 2-F modification or with bridged sugars such as oxyalkylene linkages between 2-oxygen and 4-carbon, have been synthesized as 2-MOE, 2-F RNA, 2,4-BNA/LNA and ENA oligonucleotides. They have shown properties of higher affinity to complementary single-stranded RNA and DNA than those of PS ODNs due to their preorganized N-conformation. On the basis of the properties of these newly designed oligonucleotides, their in vitro and in vivo applications for gene silencing as true antisense oligonucleotides have been reported. In this review, antisense applications with these modified oligonucleotides are focused on.
Export Options
About this article
Cite this article as:
Koizumi Makoto, True Antisense Oligonucleotides with Modified Nucleotides Restricted in the Nconformation, Current Topics in Medicinal Chemistry 2007; 7 (7) . https://dx.doi.org/10.2174/156802607780487768
DOI https://dx.doi.org/10.2174/156802607780487768 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteomic and Glycomic Markers to Differentiate Lung Adenocarcinoma from COPD
Current Medicinal Chemistry Biomarkers in Non-Small Cell Lung Cancer: Perspectives of Individualized Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Advances Towards The Discovery of GPR55 Ligands
Current Medicinal Chemistry Disodium Phosphate of Novel Pyrazole-Linked Norcantharidin Analogs:Design, Synthesis and their Anticancer Evaluation
Letters in Drug Design & Discovery Circulating Advanced Oxidation Protein Products as Oxidative Stress Biomarkers and Progression Mediators in Pathological Conditions Related to Inflammation and Immune Dysregulation
Current Medicinal Chemistry Antioxidant and Cytotoxicity Activity of Phenolic Compounds from Piper sarmentosum Roxb. Against T47D Human Breast Cancer Cell
The Natural Products Journal Anti-Tumor Effects of Osthole on Different Malignant Tissues: A Review of Molecular Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics The Other Side of the Opioid Story: Modulation of Cell Growth and Survival Signaling
Current Medicinal Chemistry Signal Transduction Inhibitors in the Treatment of Breast Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Target Recognition Molecules and Molecular Modeling Studies
Current Topics in Medicinal Chemistry Multidrug Resistance Through the Spectacle of P-Glycoprotein
Current Cancer Drug Targets Dyspnea in Cancer Patients: A Well-Known and Neglected Symptom
Reviews on Recent Clinical Trials The Genetic and Epigenetic Effects of 5-Azacytidine and its Major Breakdown Product Guanylurea
Epigenetic Diagnosis & Therapy (Discontinued) A 1536-Well Fluorescence Polarization Assay to Screen for Modulators of the MUSASHI Family of RNA-Binding Proteins
Combinatorial Chemistry & High Throughput Screening Assessment of Nutritional Status in Cancer – The Relationship Between Body Composition and Pharmacokinetics
Anti-Cancer Agents in Medicinal Chemistry Interleukin-24: A Molecule with Potential Anti-Cancer Activity and a Cytokine in Search of a Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Optimisation of DMPK by the Inhaled Route: Challenges and Approaches
Current Drug Metabolism Experience with Indium-111 and Yttrium-90-Labeled Somatostatin Analogs
Current Pharmaceutical Design Targeting the Eph-ephrin System with Protein-Protein Interaction (PPI) Inhibitors
Current Drug Targets